Aytu Biopharma (AYTU) Gains from Investment Securities (2018 - 2022)

Aytu Biopharma (AYTU) has 5 years of Gains from Investment Securities data on file, last reported at $75000.0 in Q4 2022.

• On a quarterly basis, Gains from Investment Securities fell 72.92% year-over-year to $75000.0 in Q4 2022; TTM through Dec 2023 was -$632000.0, a 78.03% decrease from a year earlier, with the FY2023 full-year figure at -$1.0 million, down 373.93% from the prior year.
• Gains from Investment Securities for Q4 2022 stood at $75000.0, down from $550000.0 in the prior quarter.
• Over the last five years, Gains from Investment Securities for AYTU reached as high as $3.3 million in Q4 2020 and fell as low as -$10.5 million in Q2 2020.
• Historically, Gains from Investment Securities has averaged -$828613.9 across 5 years, with a median of $29500.0 in 2019.
• Across the five-year window, Gains from Investment Securities jumped 21986.67% in 2020 and tumbled 91.64% in 2021, its largest moves.
• Year by year, Gains from Investment Securities stood at $4633.0 in 2018, then soared by 223.76% to $15000.0 in 2019, then soared by 21986.67% to $3.3 million in 2020, then tumbled by 91.64% to $277000.0 in 2021, then slumped by 72.92% to $75000.0 in 2022.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $75000.0 in Q4 2022, $550000.0 in Q2 2022, and -$1.3 million in Q1 2022.